Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.

Tenenholz TC, Shields C, Ramesh VR, Tercilla O, Hagan MP.

Urol Oncol. 2007 Mar-Apr;25(2):101-9.

PMID:
17349523
2.
3.
4.

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.

Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9.

PMID:
15145150
5.
6.

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D.

J Urol. 2004 Mar;171(3):1141-7.

PMID:
14767288
7.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
8.

Hormone therapy for patients with prostate carcinoma.

Klotz L.

Cancer. 2000 Jun 15;88(12 Suppl):3009-14. Review.

PMID:
10898345
9.

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.

Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1467-71. Epub 2007 Aug 8.

PMID:
17689886
10.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
11.

External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.

Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, Shioyama Y, Araya M, Mukumoto N, Mitsumori M, Teshima T; Japanese Patterns of Care Study Working Subgroup of Prostate Cancer.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):759-65. doi: 10.1016/j.ijrobp.2008.08.067. Epub 2009 Mar 26.

PMID:
19327908
12.
13.

Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.

Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.

J Urol. 2001 Dec;166(6):2198-201.

PMID:
11696735
14.

Impact of percent positive random biopsies on biochemical outcome in prostate cancer patients treated with external beam radiotherapy with or without androgen deprivation.

Igdem S, Abacioglu U, Cetin I, Alco G, Akgun Z, Sengoz M, Bekiroglu N, Turkan S, Okkan S.

J BUON. 2009 Oct-Dec;14(4):629-34.

PMID:
20148454
15.

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.

Oefelein MG, Ricchiuti VS, Conrad PW, Goldman H, Bodner D, Resnick MI, Seftel A.

Urology. 2002 Jul;60(1):120-4.

PMID:
12100936
16.

Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients.

Coblentz TR, Bissonette EA, Williams KR, Theodorescu D.

Prostate Cancer Prostatic Dis. 2002;5(3):219-25.

17.

Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.

Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J.

Am J Clin Oncol. 2003 Oct;26(5):e119-23.

PMID:
14528085
18.

Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.

Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.

BJU Int. 2006 Jun;97(6):1184-9.

19.
20.

Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.

Pether M, Goldenberg SL, Bhagirath K, Gleave M.

Can J Urol. 2003 Apr;10(2):1809-14.

PMID:
12773232

Supplemental Content

Support Center